REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Laekna, Inc. (China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Laekna, Inc. Profile Updated: July 09, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Laekna, Inc. is engaged in the discovery, development and commercialization of innovative therapies for cancer and liver disease, and is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The Company's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor, the LAE001 is an androgen synthesis inhibitor. The company was established in 2016 and is headquartered in Hong Kong, China.

Headquarters
3-2-467, 5 Xingbin Road (Lin Li Center), Sino-Italy Ningbo Ecological Park, Yuyao
Yuyao; Zhejiang;

Contact Details: Purchase the Laekna, Inc. report to view the information.

Website: http://www.laekna.com

Basic Information
Total Employees:
Purchase the Laekna, Inc. report to view the information.
Outstanding Shares:
Purchase the Laekna, Inc. report to view the information.
Registered Capital:
Purchase the Laekna, Inc. report to view the information.
Financial Auditors:
Purchase the Laekna, Inc. report to view the information.
Incorporation Date:
July 29, 2016
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Director/Member of the Board
Ownership Details
Purchase this report to view the information.
17.73%
Purchase this report to view the information.
10.12%
Purchase this report to view the information.
9.07%
Purchase this report to view the information.
Purchase this report to view the information.
Subsidiaries
Laekna Limited (Hong Kong SAR, China)
100%
Laekna Llc (United States)
100%
Laekna Pharmaceutical Shanghai Co., Ltd.
Company Performance
Financial values in the chart are available after Laekna, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Total operating revenue
85.39%▲
Operating profit (EBIT)
28.78%▲
EBITDA
-13.33%▼
Net Profit (Loss) for the Period
33.77%▲
Total assets
-23.3%▼
Total equity
-29.7%▼
Return on Equity (ROE)
1.31%▲
Debt to Equity Ratio
4.41%▲
Quick Ratio
-4.91%▼
Cash Ratio
-6.02%▼

Similar companies

Wuxi Apptec Co.,Ltd.
 
Zjamp Group Co., Ltd.
Sinopharm Group Company Limited
 
Shanghai Pharmaceuticals Holding Co.,Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
 
Nanjing Pharmaceutical Company Limited
Chongqing Zhifei Biological Products Co.,Ltd.
 
Hubei Biocause Pharmaceutical Co.,Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (上海复星医药(集团)股份有限公司)
 
I-Mab Inc.

Related EMIS Industry Reports

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo